West Pharmaceutical Services Inc. (WST) Expected to Announce Quarterly Sales of $435.00 Million

Analysts predict that West Pharmaceutical Services Inc. (NYSE:WST) will announce sales of $435.00 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for West Pharmaceutical Services’ earnings. The lowest sales estimate is $430.00 million and the highest is $440.00 million. West Pharmaceutical Services posted sales of $415.60 million in the same quarter last year, which suggests a positive year over year growth rate of 4.7%. The company is scheduled to report its next earnings report on Thursday, February 21st.

On average, analysts expect that West Pharmaceutical Services will report full year sales of $1.73 billion for the current financial year, with estimates ranging from $1.72 billion to $1.73 billion. For the next fiscal year, analysts forecast that the business will post sales of $1.85 billion, with estimates ranging from $1.84 billion to $1.86 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for West Pharmaceutical Services.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, October 25th. The medical instruments supplier reported $0.76 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.70 by $0.06. West Pharmaceutical Services had a net margin of 9.06% and a return on equity of 15.78%. The firm had revenue of $431.70 million for the quarter, compared to analysts’ expectations of $427.55 million.

WST has been the topic of several recent analyst reports. ValuEngine raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Wednesday, October 17th. Zacks Investment Research raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $135.00 target price on the stock in a research report on Saturday, October 13th.

Shares of West Pharmaceutical Services stock traded down $0.03 during mid-day trading on Friday, hitting $103.83. 156,805 shares of the stock were exchanged, compared to its average volume of 376,313. West Pharmaceutical Services has a 12 month low of $82.74 and a 12 month high of $125.09. The company has a quick ratio of 2.23, a current ratio of 2.94 and a debt-to-equity ratio of 0.15. The stock has a market cap of $7.69 billion, a P/E ratio of 37.35, a P/E/G ratio of 3.68 and a beta of 1.21.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 6th. Investors of record on Wednesday, January 23rd will be issued a $0.15 dividend. The ex-dividend date is Tuesday, January 22nd. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.58%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 21.58%.

Large investors have recently bought and sold shares of the stock. Riverbridge Partners LLC raised its holdings in shares of West Pharmaceutical Services by 37.8% in the 3rd quarter. Riverbridge Partners LLC now owns 647,980 shares of the medical instruments supplier’s stock worth $80,006,000 after purchasing an additional 177,637 shares during the period. Marshall Wace LLP raised its holdings in shares of West Pharmaceutical Services by 614.6% in the 3rd quarter. Marshall Wace LLP now owns 99,369 shares of the medical instruments supplier’s stock worth $12,269,000 after purchasing an additional 85,464 shares during the period. Macquarie Group Ltd. raised its holdings in shares of West Pharmaceutical Services by 0.7% in the 2nd quarter. Macquarie Group Ltd. now owns 107,213 shares of the medical instruments supplier’s stock worth $10,645,000 after purchasing an additional 786 shares during the period. Prudential Financial Inc. raised its holdings in shares of West Pharmaceutical Services by 145.2% in the 3rd quarter. Prudential Financial Inc. now owns 218,492 shares of the medical instruments supplier’s stock worth $26,977,000 after purchasing an additional 129,400 shares during the period. Finally, Intermede Investment Partners Ltd raised its holdings in shares of West Pharmaceutical Services by 4.1% in the 3rd quarter. Intermede Investment Partners Ltd now owns 253,071 shares of the medical instruments supplier’s stock worth $31,247,000 after purchasing an additional 10,078 shares during the period. 92.50% of the stock is currently owned by institutional investors.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Featured Article: Consumer Price Index (CPI)

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply